ValueAct Capital, LLC
http://www.valueact.com/ValueAct Capital, LLC is a San Francisco based hedge fund. The firm offers its services to high net worth individuals and institutions while investing in the public equity and hedging markets of the United States. VAC primarily invests in share re-purchase programs, public market recapitalizations, de-leveraging equity infusions, off-balance sheet financings, and going-private transactions. The fund invests in companies with market capitalizations ranging from $150 million to $1.5 billion and typically invests $25 million to $100 million per investment. In addition, VAC sometimes invests in private companies depending on the growth opportunities.
View Older Stories View More Recent Stories
-
Barclays Reiterates an 'Underweight' on Kar Auction (KAR); Rumor Dissected
-
MKM Partners Maintains a 'Neutral' on Gardner Denver Corp. (GD); Not So Fast ValueAct
-
ValueAct Capital Lowers Stake in VeriSign, Inc. (VRSN) to 5.36%
-
ValueAct Capital Shows New ~6% Stake in CBRE Group (CBG)
-
ValueAct Capital Shows New 5% Stake in Adobe Systems (ADBE)
-
Barclays Maintains an 'Overweight' on Gartner (IT); Buys Remaining ValueAct Shares
-
Gartner (IT) to Buy Back ValueAct Stake at $35.20/Share
-
Barclays on Information Services: C&I Loans Up, Revolving Credit Continues Sideways; DNB/data.com; IT Insider Selling
-
Notable Mergers and Acquisitions of the Day 10/11:
-
ARRIS Group (ARRS) to Acquire BigBand (BBND) for $2.24/Share
-
ValueAct Capital Liquidates Stake in Alere (ALR)
-
ValueAct Capital Raises Stake in VeriSign, Inc. (VRSN) to 5.3%
-
ValueAct Capital Raises Stake in Moodys Corp. (MCO) to 6.09%
-
ValueAct Capital Shows New 5.9% Stake in Motorola Solutions (MSI)
-
ValueAct Sells Nearly 2M Shares of VeriSign (VRSN)
-
Gartner (IT) Prices 8M Secondary Common Offering at $35.50/Share
-
Gartner (IT) Announces 8M Common Secondary Offering
-
Allscripts (MDRX) and Eclipsys (ECLP) Announce Reduction of Secondary Offering by 11M Common
-
Valeant (VRX) And Biovail (BVF) Announces Merger Agreement
-
ValueAct Capital Lifts Stake In Snap-on (SNA) to 5.3%
-
Shares of Valeant Pharmaceuticals (VRX) Up Over 20% in Past Six Sessions
-
Valeant Pharma (VRX) Tops Q1 Views; Raises FY10 EPS Guidance; to Buy Aton Pharma for $318M
-
ValueAct Capital Amasses 5.3% Stake in Immucor (BLUD)
-
ValueAct SmallCap Accumulates 5.1% Stake in Immersion (IMMR)
-
ValueAct Capital Boosts Stake in Alliance Data Systems (ADS) to 5.9%
-
ValueAct Partners Continues To Boosts Stake in Chimera Investment (CIM)
-
ValueAct Boosts Stake in Chimera Investment Corp. (CIM) to 9.9%
-
ValueAct Capital Boosts Stake in Chimera Investment (CIM) To 8.2%
-
ValueAct Capital Boosts Stake in Chimera Investment (CIM) To 6.7%
-
ValueAct Capital Lowers Stake in International Rectifier (IRF) to 3.8%
-
Buckingham Research Upgrades Omnicare (OCR) to Accumulate
-
Unusual 11 Mid-Day Movers 2/22: OPTV, ESST, NCI, FRPT Higher; BRLC, OFIX, UNFI, CBEY Lower
-
Omnicare (OCR) 10% Higher After ValueAct's Ubben Joins Board
-
ValueAct Capital Raises Stake in Sara Lee (SLE) to 6.1%
-
Following Eddie: Could Acxiom (ACXM) Be Worth A Look?
-
ValueAct Capital Discloses 5.2% Stake in International Rectifier (IRF)
-
ValueAct Capital Discloses 5% Stake in Sealy (ZZ)
-
ValueAct Capital Discloses 5% Stake in Sara Lee (SLE)
-
ValueAct Capital Boosts Stake in Equifax (EFX) to 7.2%

